ArticleJournal of medicine and life2025
Surgical excision of cerebral glioma and multimodal treatment including Cerebrolysin: a case report.
Article in Journal of medicine and life, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Salvianolic Acid B Attenuates Excitotoxic Neuronal Injury After Transient Cerebral Ischemia.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multimodal treatment of patients with a brain tumor primarily involves microsurgical excision, ideally radical, or at least subtotal resection. Tumors in deep or inaccessible locations may require biopsy followed by adjuvant therapy with chemotherapy, radiotherapy, or radiosurgery. Beyond controlling tumor growth, preserving neurological function and promoting brain plasticity are essential goals. Persistent inflammation and intracranial hypertension can trigger secondary injury through edema, excitotoxicity, and ischemia, potentially resulting in irreversible neuronal damage. Multimodal strategies, including neuroprotective measures such as Cerebrolysin administration, may help prevent or mitigate these secondary processes, supporting recovery and functional outcomes. Clinically, patients may present with headache, nausea, vomiting, seizures, or subtle cognitive and motor deficits, progressing in severe cases to deterioration of consciousness. Incorporating cerebroprotective interventions in perioperative management represents a promising approach to enhance recovery, functional independence, and quality of life in neurosurgical oncology patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.